Search

Genfit

Cerrado

SectorSalud

3.72 0.7

Resumen

Variación precio

24h

Actual

Mínimo

3.66

Máximo

3.734

Métricas clave

By Trading Economics

Ingresos

19M

-10M

Ventas

28M

36M

P/B

Media del Sector

104.267

37.461

Margen de beneficio

-28.017

Empleados

188

EBITDA

25M

955K

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+125.29% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

25M

189M

Apertura anterior

3.02

Cierre anterior

3.72

Noticias sobre sentimiento de mercado

By Acuity

29%

71%

62 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Genfit Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

24 oct 2025, 18:41 UTC

Ganancias

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 oct 2025, 18:31 UTC

Ganancias

Correction to Procter & Gamble to Focus on Innovation

24 oct 2025, 16:25 UTC

Principales Movimientos del Mercado

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 oct 2025, 21:24 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 oct 2025, 21:24 UTC

Charlas de Mercado

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 oct 2025, 21:07 UTC

Ganancias

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 oct 2025, 20:58 UTC

Ganancias

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 oct 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

24 oct 2025, 20:40 UTC

Ganancias

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 oct 2025, 20:24 UTC

Ganancias

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct 2025, 20:23 UTC

Ganancias

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct 2025, 20:13 UTC

Ganancias

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct 2025, 20:07 UTC

Charlas de Mercado

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 oct 2025, 19:40 UTC

Charlas de Mercado

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 oct 2025, 19:35 UTC

Charlas de Mercado

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 oct 2025, 19:33 UTC

Ganancias

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 oct 2025, 19:29 UTC

Charlas de Mercado

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 oct 2025, 18:52 UTC

Ganancias

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 oct 2025, 18:41 UTC

Ganancias

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 oct 2025, 18:03 UTC

Ganancias

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 oct 2025, 18:02 UTC

Ganancias

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 oct 2025, 18:00 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 oct 2025, 16:57 UTC

Ganancias

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 oct 2025, 16:54 UTC

Charlas de Mercado

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 oct 2025, 16:44 UTC

Charlas de Mercado
Ganancias

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 oct 2025, 16:39 UTC

Charlas de Mercado
Ganancias

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 oct 2025, 16:33 UTC

Ganancias

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct 2025, 16:23 UTC

Ganancias

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct 2025, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

24 oct 2025, 16:07 UTC

Ganancias

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Genfit Esperado

Precio Objetivo

By TipRanks

125.29% repunte

Estimación a 12 meses

Media 8.403 EUR  125.29%

Máximo 8.4 EUR

Mínimo 8.4 EUR

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Genfit Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

1

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

3.566 / 4.12Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

62 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
help-icon Live chat